Karina A. Keogh, M.D.

Closed for Enrollment

• A Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics (CHINOOK) (CHINOOK) Rochester, Minn.

  The purposes of this study are to evaluate the effect of benralizumab on submucosal eosinophils in endobronchial biopsies as measured by major basic protein (MBP) staining, and to evaluate the effect of treatment with benralizumab on airway wall dimensions as measured by QCT imaging.

   

• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center 24-Week Study to Evaluate the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects with Severe Eosinophilic Asthma on Markers of Asthma Control Rochester, Minn.

  The purpose of this study is to evaluate the effectiveness and safety of mepolizumab adjunctive therapy in participants with severe eosinophilic asthma by measuring it on markers of asthma control. The overall intent of the current study is to more fully explore the impact of mepolizumab on health-related quality of life and other measures of asthma control, including lung function.